Vor Biopharma (VOR) Stock Forecast, Price Target & Predictions
VOR Stock Forecast
Vor Biopharma stock forecast is as follows: an average price target of $6.00 (represents a 669.23% upside from VOR’s last price of $0.78) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
VOR Price Target
The average price target for Vor Biopharma (VOR) is $6.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 669.23% upside from VOR's last price of $0.78.
VOR Analyst Ratings
According to 4 Wall Street analysts, Vor Biopharma's rating consensus is 'Buy'. The analyst rating breakdown for VOR stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Vor Biopharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 27, 2022 | - | Goldman Sachs | $6.00 | $5.60 | 7.14% | 669.23% |
The latest Vor Biopharma stock forecast, released on Apr 27, 2022 by Goldman Sachs company, set a price target of $6.00, which represents a 7.14% increase from the stock price at the time of the forecast ($5.60), and a 669.23% increase from VOR last price ($0.78).
Vor Biopharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.78 | $0.78 | $0.78 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Vor Biopharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Vor Biopharma's last price of $0.78. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 06, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 14, 2024 | Barclays | Overweight | Overweight | Hold |
| Nov 14, 2022 | Oppenheimer | Outperform | Outperform | Hold |
| Jul 27, 2022 | Wedbush | - | Outperform | Initialise |
Vor Biopharma's last stock rating was published by H.C. Wainwright on Sep 06, 2024. The company gave VOR a "Buy" rating, the same as its previous rate.
Vor Biopharma Financial Forecast
Vor Biopharma Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Vor Biopharma's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. VOR's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Vor Biopharma EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict VOR's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Vor Biopharma's previous annual EBITDA (undefined) of $NaN.
Vor Biopharma Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-25.10M | $-23.82M | $-20.73M | $-20.34M | $-21.23M | $-27.47M | $-28.53M |
| High Forecast | $-25.10M | $-23.82M | $-20.73M | $-20.34M | $-21.23M | $-24.72M | $-28.53M |
| Low Forecast | $-25.10M | $-23.82M | $-20.73M | $-20.34M | $-21.23M | $-29.53M | $-28.53M |
| Surprise % | - | - | - | - | - | - | - |
Vor Biopharma's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. VOR's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Vor Biopharma SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Vor Biopharma's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to VOR last annual SG&A of $NaN (undefined).
Vor Biopharma EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.37 | $-0.35 | $-0.30 | $-0.30 | $-0.31 | $-0.40 | $-0.42 |
| High Forecast | $-0.37 | $-0.35 | $-0.30 | $-0.30 | $-0.31 | $-0.36 | $-0.42 |
| Low Forecast | $-0.37 | $-0.35 | $-0.30 | $-0.30 | $-0.31 | $-0.43 | $-0.42 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Vor Biopharma's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to VOR previous annual EPS of $NaN (undefined).
Vor Biopharma Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ACET | Adicet Bio | $1.26 | $32.50 | 2479.37% | Buy |
| VTYX | Ventyx Biosciences | $2.15 | $33.86 | 1474.88% | Buy |
| STTK | Shattuck Labs | $1.16 | $12.00 | 934.48% | Hold |
| VOR | Vor Biopharma | $0.78 | $6.00 | 669.23% | Buy |
| AUTL | Autolus Therapeutics | $3.34 | $9.50 | 184.43% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.81 | $38.80 | 161.99% | Buy |
| ERAS | Erasca | $2.87 | $7.00 | 143.90% | Buy |
| FHTX | Foghorn Therapeutics | $8.24 | $16.33 | 98.18% | Buy |
| CGEM | Cullinan Oncology | $15.92 | $31.50 | 97.86% | Buy |
| LYRA | Lyra Therapeutics | $0.26 | $0.50 | 92.31% | Hold |
| DSGN | Design Therapeutics | $5.32 | $9.67 | 81.77% | Buy |
| KNSA | Kiniksa Pharmaceuticals | $21.48 | $36.33 | 69.13% | Buy |
| BOLT | Bolt Biotherapeutics | $0.67 | $1.00 | 49.25% | Hold |
| EWTX | Edgewise Therapeutics | $34.48 | $45.00 | 30.51% | Buy |
| NRIX | Nurix Therapeutics | $25.04 | $32.20 | 28.59% | Buy |
| NUVL | Nuvalent | $89.53 | $107.83 | 20.44% | Buy |
| KYMR | Kymera Therapeutics | $47.07 | $51.50 | 9.41% | Buy |
| ACLX | Arcellx | $86.44 | $71.57 | -17.20% | Buy |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |
VOR Forecast FAQ
Is Vor Biopharma a good buy?
Yes, according to 4 Wall Street analysts, Vor Biopharma (VOR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of VOR's total ratings.
What is VOR's price target?
Vor Biopharma (VOR) average price target is $6 with a range of $6 to $6, implying a 669.23% from its last price of $0.78. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Vor Biopharma stock go up soon?
According to Wall Street analysts' prediction for VOR stock, the company can go up by 669.23% (from the last price of $0.78 to the average price target of $6), up by 669.23% based on the highest stock price target, and up by 669.23% based on the lowest stock price target.
Can Vor Biopharma stock reach $1?
VOR's average twelve months analyst stock price target of $6 supports the claim that Vor Biopharma can reach $1 in the near future.
What are Vor Biopharma's analysts' financial forecasts?
Vor Biopharma's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-77.232M (high $-74.485M, low $-79.292M), average SG&A $0 (high $0, low $0), and average EPS is $-1.131 (high $-1.091, low $-1.161). VOR's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-89.994M (high $-89.994M, low $-89.994M), average SG&A $0 (high $0, low $0), and average EPS is $-1.318 (high $-1.318, low $-1.318).